EP0170006A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents
Assignee: Wyeth Holdings LLC
•
Filing: 1985-06-03
•
Granted: —
•
Expires: 2005-06-03
Abstract
Abstract The present invention relates to novel agents, to their production by fermentation, to methods for their recovery and concentration from crude solutions, to processes for their purification and to pharmaceutically end pharmacologically-acceptable salts thereof. Also, this invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals. and poultry. by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249 α, β, γ, δ, ε, ζ, η, 6, , κ, λ, µ, v, and ω or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations and other insecticidal activities. These novel agents are produced via a controlled condition microbiological fermentation using Streptomyces cyaneogriseus ssp. noncyanogenus, designated LL- F28249 and having deposited accession number NRRL 15773.
Inventors
- 👤 Irwin Bovden Wood
- 👤 John Anthony Pankavich
- 👤 Guy Thomas Carter
- 👤 Margaret Jennings Torrey
- 👤 Michael Greenstein
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 16:52
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/01; A; A01; A01N; A01N63/00; A01N63/20; A01N63/28; A61; A61P; A61P33/00; A61P33/10; C12; C12N; C12N1/00; C12N1/20; C12N1/205; C12P; C12P1/00; C12P1/06; C12R; C12R2001/00; C12R2001/01; C12R2001/465
Claims Analysis
Total Claims: 52
Claim 1
Independent Claim
136 words
The compound designated LL-F28249a wherein the compound has: a) a molecular weight of 612 (FAB-MS); b) a molecular formula, C 36 H 52 O 8 ; c) a specific optical rotation, [α] 26 D = +133±3° (C 0.3, acetone); d) a characteristic ultraviolet absorption spectrum as shown in Figure I of the attached drawings; e) a characteristic infrared absorption spectrum as shown in Figure II of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure III of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure IV of the attached draw- h) a characteristic electron impact mass spectrum as shown in Figure V of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 2
Dependent Claim
136 words
The compound designated LL-F28249a wherein the compound has: a) a molecular weight of 612 (FAB-MS); b) a molecular formula, C 36 H 52 O 8 ; c) a specific optical rotation, [α] 26 D = +133±3° (C 0.3, acetone); d) a characteristic ultraviolet absorption spectrum as shown in Figure I of the attached drawings; e) a characteristic infrared absorption spectrum as shown in Figure II of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure III of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure IV of the attached draw- h) a characteristic electron impact mass spectrum as shown in Figure V of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 3
Dependent Claim
133 words
The compound designated LL-F282498 wherein the compound has: a) a molecular weight of 584 (FAB-MS); b) a molecular formula, C 34 H 48 O 8 ; c) specific optical rotation: [a] 26 D =+125° (C 0.30, acetone). d) a characteristic ultraviolet absorption spectrum as shown in Figure VI of the attached drawings; _e) a characteristic infrared absorption spectrum as shown in Figure VII of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure VIII of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure XXXVIII of the attached h) a characteristic electron impact mass spectrum as shown in Figure IX of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 4
Dependent Claim
133 words
The compound designated LL-F282498 wherein the compound has: a) a molecular weight of 584 (FAB-MS); b) a molecular formula, C 34 H 48 O 8 ; c) specific optical rotation: [a] 26 D =+125° (C 0.30, acetone). d) a characteristic ultraviolet absorption spectrum as shown in Figure VI of the attached drawings; _e) a characteristic infrared absorption spectrum as shown in Figure VII of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure VIII of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure XXXVIII of the attached h) a characteristic electron impact mass spectrum as shown in Figure IX of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 5
Dependent Claim
136 words
The compound designated LL-F28249y wherein the compound has: a) a molecular weight of 598 (FAB-MS); b) a molecular formula, C 35 H 50 O 8 ; c) a specific optical rotation: [α] 26 D = +150°±4° (C 0.3, acetone); d) a characteristic ultraviolet absorption spectrum as shown in Figure X of the attached drawings; e) a characteristic infrared absorption spectrum as shown in Figure XI of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XII of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure XIII of the attached draw- h) a characteristic electron impact mass spectrum as shown in Figure XIV of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 6
Dependent Claim
136 words
The compound designated LL-F28249y wherein the compound has: a) a molecular weight of 598 (FAB-MS); b) a molecular formula, C 35 H 50 O 8 ; c) a specific optical rotation: [α] 26 D = +150°±4° (C 0.3, acetone); d) a characteristic ultraviolet absorption spectrum as shown in Figure X of the attached drawings; e) a characteristic infrared absorption spectrum as shown in Figure XI of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XII of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure XIII of the attached draw- h) a characteristic electron impact mass spectrum as shown in Figure XIV of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 7
Dependent Claim
136 words
The compound designated LL-F28249ω wherein the compound has: a) a molecular weight of 806 (FAB-MS); b ) a molecular formula, C 45 H 74 0 12 ; c) a specific optical rotation: [α] 26 D = -49±4° (C 0.35, methanol); d) a characteristic ultraviolet absorption spectrum as shown in Figure XV of the attached drawings; e) a characteristic infrared absorption spectrum as shown in Figure XVI of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XVII of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure XVIII of the attached h) a characteristic electron impact mass spectrum as shown in Figure XIX of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 8
Dependent Claim
136 words
The compound designated LL-F28249ω wherein the compound has: a) a molecular weight of 806 (FAB-MS); b ) a molecular formula, C 45 H 74 0 12 ; c) a specific optical rotation: [α] 26 D = -49±4° (C 0.35, methanol); d) a characteristic ultraviolet absorption spectrum as shown in Figure XV of the attached drawings; e) a characteristic infrared absorption spectrum as shown in Figure XVI of the attached drawings; f) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XVII of the attached drawings; g) a characteristic carbon-13 nuclear magnetic resonance spectrum as shown in Figure XVIII of the attached h) a characteristic electron impact mass spectrum as shown in Figure XIX of the attached drawings with measured m/z values and proposed elemental compositions as indicated below obtained by high resolution mass measurements,
Claim 9
Dependent Claim
81 words
The compound designated LL-F28249δ wherein the compound has: a) a molecular weight of 616 (EI-MS); b) a molecular formula, C 35 H 52 O 9 ; c) a HPLC retention volume of 14.0 ml; d) a characteristic ultraviolet absorption spectrum shown in Figure XX of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXI of the attached draw- f) a characteristic electron impact mass spectrum as shown in Figure XXII of the attached drawings.
Claim 10
Dependent Claim
81 words
The compound designated LL-F28249δ wherein the compound has: a) a molecular weight of 616 (EI-MS); b) a molecular formula, C 35 H 52 O 9 ; c) a HPLC retention volume of 14.0 ml; d) a characteristic ultraviolet absorption spectrum shown in Figure XX of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXI of the attached draw- f) a characteristic electron impact mass spectrum as shown in Figure XXII of the attached drawings.
Claim 11
Dependent Claim
82 words
The compound designated LL-F28249ε wherein the compound has: a) a molecular weight of 598 (EI-MS); b) molecular formula, C 35 H 50 O 8 ; c) a HPLC retention volume of 14.8 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXIII of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXIV of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXV of the attached drawings.
Claim 12
Dependent Claim
82 words
The compound designated LL-F28249ε wherein the compound has: a) a molecular weight of 598 (EI-MS); b) molecular formula, C 35 H 50 O 8 ; c) a HPLC retention volume of 14.8 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXIII of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXIV of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXV of the attached drawings.
Claim 13
Dependent Claim
84 words
The compound designated LL-F28249 ζ wherein the compound has: a) a molecular weight of 598 (EI-MS); b) a molecular formula, C 35 H 50 O 8 ; c) a HPLC retention volume of 16.0 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXVI of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXVII of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXVIII of the attached drawings.
Claim 14
Dependent Claim
84 words
The compound designated LL-F28249 ζ wherein the compound has: a) a molecular weight of 598 (EI-MS); b) a molecular formula, C 35 H 50 O 8 ; c) a HPLC retention volume of 16.0 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXVI of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXVII of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXVIII of the attached drawings.
Claim 15
Dependent Claim
83 words
The compound designated LL-F28249 ηwherein the compound has: a) a molecular weight of 612 (EI-MS); b) a molecular formula, C 36 H 52 O 8 ; c) a HPLC retention value of 23.5 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXIX of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXX of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXXI of the attached drawings.
Claim 16
Dependent Claim
83 words
The compound designated LL-F28249 ηwherein the compound has: a) a molecular weight of 612 (EI-MS); b) a molecular formula, C 36 H 52 O 8 ; c) a HPLC retention value of 23.5 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXIX of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXX of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXXI of the attached drawings.
Claim 17
Dependent Claim
83 words
The compound designated LL-F28249e wherein the compound has: a) a molecular weight of 626 (EI-MS); b) a molecular formula, C 37 H 54 O 8 ; c) a HPLC retention value of 24.5 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXXII of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXXIII of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXXIV of the attached drawings.
Claim 18
Dependent Claim
83 words
The compound designated LL-F28249e wherein the compound has: a) a molecular weight of 626 (EI-MS); b) a molecular formula, C 37 H 54 O 8 ; c) a HPLC retention value of 24.5 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXXII of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXXIII of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXXIV of the attached drawings.
Claim 19
Dependent Claim
84 words
The compound designated LL-F28249 l wherein the compound has: a) a molecular weight of 626 (EI-MS); b) a molecular formula, C 37 H 54 O 8 ; c) a HPLC retention value of 26.0 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXXV of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXXVI of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXXVII of the attached drawings.
Claim 20
Dependent Claim
84 words
The compound designated LL-F28249 l wherein the compound has: a) a molecular weight of 626 (EI-MS); b) a molecular formula, C 37 H 54 O 8 ; c) a HPLC retention value of 26.0 ml; d) a characteristic ultraviolet absorption spectrum as shown in Figure XXXV of the attached drawings; e) a characteristic proton nuclear magnetic resonance spectrum as shown in Figure XXXVI of the attached drawings; and f) a characteristic electron impact mass spectrum as shown in Figure XXXVII of the attached drawings.
Claim 21
Dependent Claim
104 words
The compound designated LL-F28249 K wherein the compound has: a) molecular weight 584 (EI-MS); b) molecular formula: C 35 H 52 O 7 ; c) Specific optical rotation: [α] D =+189°-(C 0.165 acetone); d) Ultraviolet absorption spectrum: as shown in Figure XXXIX UV CH 3 OH MAX 241nm (E20,400); e) Infrared absorption spectrum: as shown in Figure XL (KBr disc); f) Electron impact mass spectrum: as shown in Figure XLI; g) Proton nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure XLII; and h) Carbon-13 nuclear magnetic resonance spectrum (CDC1 3 ); as shown in Figure XLIII and described in Table IX.
Claim 22
Dependent Claim
104 words
The compound designated LL-F28249 K wherein the compound has: a) molecular weight 584 (EI-MS); b) molecular formula: C 35 H 52 O 7 ; c) Specific optical rotation: [α] D =+189°-(C 0.165 acetone); d) Ultraviolet absorption spectrum: as shown in Figure XXXIX UV CH 3 OH MAX 241nm (E20,400); e) Infrared absorption spectrum: as shown in Figure XL (KBr disc); f) Electron impact mass spectrum: as shown in Figure XLI; g) Proton nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure XLII; and h) Carbon-13 nuclear magnetic resonance spectrum (CDC1 3 ); as shown in Figure XLIII and described in Table IX.
Claim 23
Dependent Claim
105 words
The compound designated LL-F28249λ wherein . the compound has: a) molecular weight: 626 (FAB-MS); b) Molecular formula: C 37 H 54 O 8 ; c) specific optical rotation: [α] 26 D =+145°(C, 0.23 acetone); d) Ultraviolet absorption spectrum: as shown in Figure XLIV UV CH 3 OH MAX =244nm (E30,000); e) Infrared absorption spectrum: as shown in Figure XLV (KBr disc); f) Electron impact mass spectrum: as shown in Figure XLVI; g) Proton nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure XLVII; and h) Carbon-13 nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure XLVIII and described in Table X.
Claim 24
Dependent Claim
105 words
The compound designated LL-F28249λ wherein . the compound has: a) molecular weight: 626 (FAB-MS); b) Molecular formula: C 37 H 54 O 8 ; c) specific optical rotation: [α] 26 D =+145°(C, 0.23 acetone); d) Ultraviolet absorption spectrum: as shown in Figure XLIV UV CH 3 OH MAX =244nm (E30,000); e) Infrared absorption spectrum: as shown in Figure XLV (KBr disc); f) Electron impact mass spectrum: as shown in Figure XLVI; g) Proton nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure XLVII; and h) Carbon-13 nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure XLVIII and described in Table X.
Claim 25
Dependent Claim
73 words
The compound designated LL-F28249µ wherein the compound has: , a) molecular weight: 612 (EI-MS); b) molecular formula: C 37 H 56 O 7 ; c) Ultraviolet absorption spectrum: as shown in Figure XLIX UV CH 3 OH MAX =241nm (E16,800); d) Infrared absorption spectrum: as shown in Figure L (KBr disc); e) Electron impact mass spectrum: as shown in Figure LI; f) Proton nuclear magnetic resonance spectrum (CDC13); as shown in Figure LII.
Claim 26
Dependent Claim
73 words
The compound designated LL-F28249µ wherein the compound has: , a) molecular weight: 612 (EI-MS); b) molecular formula: C 37 H 56 O 7 ; c) Ultraviolet absorption spectrum: as shown in Figure XLIX UV CH 3 OH MAX =241nm (E16,800); d) Infrared absorption spectrum: as shown in Figure L (KBr disc); e) Electron impact mass spectrum: as shown in Figure LI; f) Proton nuclear magnetic resonance spectrum (CDC13); as shown in Figure LII.
Claim 27
Dependent Claim
107 words
The compound designated LL-F28249v wherein the compound has: a) molecular weight: 592 (EI-MS); b) molecular formula: C 36 H 48 O 7 ; c) specific optical rotation: [α] 26 D +131°(C .325, acetone); d) Ultraviolet absorption spectrum: as shown in Figure LIII UV CH 3 OH MAX =256 (E20,500); 358 (E 8,&30); e) Infrared absorption spectrum: as shown in Figure LIV (KBr disc); f) Electron impact mass spectrum: as shown in Figure LV; g) Proton nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure LVI; and h) Carbon-13 nuclear magnetic resonance spectrum (CDC1 3 ); as shown in Figure LVII, and described in Table XI.
Claim 28
Dependent Claim
107 words
The compound designated LL-F28249v wherein the compound has: a) molecular weight: 592 (EI-MS); b) molecular formula: C 36 H 48 O 7 ; c) specific optical rotation: [α] 26 D +131°(C .325, acetone); d) Ultraviolet absorption spectrum: as shown in Figure LIII UV CH 3 OH MAX =256 (E20,500); 358 (E 8,&30); e) Infrared absorption spectrum: as shown in Figure LIV (KBr disc); f) Electron impact mass spectrum: as shown in Figure LV; g) Proton nuclear magnetic resonance spectrum (CDCl 3 ); as shown in Figure LVI; and h) Carbon-13 nuclear magnetic resonance spectrum (CDC1 3 ); as shown in Figure LVII, and described in Table XI.
Claim 29
Dependent Claim
103 words
A process for producing agents LL-F28249a, LL-F28249β, LL-F28249y, LL-F28249δ, LL-F28249ε, LL-F28249ζ, LL-F28249n, LL-F28249θ, LL-F28249, LL-F28249K, LL-F28249X, LL-F28249µ, LL-F28249v, and LL-F28249w which comprises: aerobically fermenting the organism Streptomyces cyaneogriseus noncyanegenus, NRRL 15773 or an LL-F28249a, β, γ, δ, c, ζ, η, e, , K, λ, µ, ν and w producing mutant thereof, in a liquid medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations, until a substantial amount of LL-F28249α,β , γ, δ, ε , ζ , η, θ , , κ , λ , µ , ν and ω are produced in said medium; and then recovering the agents therefrom.
Claim 30
Dependent Claim
103 words
A process for producing agents LL-F28249a, LL-F28249β, LL-F28249y, LL-F28249δ, LL-F28249ε, LL-F28249ζ, LL-F28249n, LL-F28249θ, LL-F28249, LL-F28249K, LL-F28249X, LL-F28249µ, LL-F28249v, and LL-F28249w which comprises: aerobically fermenting the organism Streptomyces cyaneogriseus noncyanegenus, NRRL 15773 or an LL-F28249a, β, γ, δ, c, ζ, η, e, , K, λ, µ, ν and w producing mutant thereof, in a liquid medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations, until a substantial amount of LL-F28249α,β , γ, δ, ε , ζ , η, θ , , κ , λ , µ , ν and ω are produced in said medium; and then recovering the agents therefrom.
Claim 31
Dependent Claim
112 words
A process for producing agents LL-F28249a, LL-F28249β, LL-F28249y, LL-F282496, LL-F28249ε, LL-F28249ζ, LL-F28249n, LL-F28249e, LL-F28249 , LL-F28249K, LL-F28249x, LL-F28249µ, LL-F28249v, and LL-F28249ω which comprises: aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations, which medium has been inoculated with a viable culture of the organism Streptomyces cyaneogriseus noncyanogenus, NRRL 15773 or an LL-F28249α,β , γ , δ , ε , ζ , η , θ, , κ, λ, µ, ν and ω producing mutant thereof; maintaining said fermentation culture with sterile aeration and agitation at a temperature of 24 0- 32 0 C for a period of 80-200 hours; harvesting the mash; and extracting the agents.
Claim 32
Dependent Claim
112 words
A process for producing agents LL-F28249a, LL-F28249β, LL-F28249y, LL-F282496, LL-F28249ε, LL-F28249ζ, LL-F28249n, LL-F28249e, LL-F28249 , LL-F28249K, LL-F28249x, LL-F28249µ, LL-F28249v, and LL-F28249ω which comprises: aerobically fermenting a liquid medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations, which medium has been inoculated with a viable culture of the organism Streptomyces cyaneogriseus noncyanogenus, NRRL 15773 or an LL-F28249α,β , γ , δ , ε , ζ , η , θ, , κ, λ, µ, ν and ω producing mutant thereof; maintaining said fermentation culture with sterile aeration and agitation at a temperature of 24 0- 32 0 C for a period of 80-200 hours; harvesting the mash; and extracting the agents.
Claim 33
Dependent Claim
60 words
A biologically pure culture of the microorganism Streptomyces cyaneogriseus noncyanogenus, NRRL 15773, said culture being capable of producing agents L L -- F28249a, LL-F28249β, LL-F28249y, LL-F28249δ, LL-F28249c, LL-F28249ζ, LL-F28249η, LL-F282496, LL-F28249 , LL-F28249K, LL-F28249λ, LL-F28249µ, LL-F28249ν, and LL-F28249 ω in recoverable quantities upon fermentation in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations.
Claim 34
Dependent Claim
60 words
A biologically pure culture of the microorganism Streptomyces cyaneogriseus noncyanogenus, NRRL 15773, said culture being capable of producing agents L L -- F28249a, LL-F28249β, LL-F28249y, LL-F28249δ, LL-F28249c, LL-F28249ζ, LL-F28249η, LL-F282496, LL-F28249 , LL-F28249K, LL-F28249λ, LL-F28249µ, LL-F28249ν, and LL-F28249 ω in recoverable quantities upon fermentation in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic anions and cations.
Claim 35
Dependent Claim
53 words
The biologically pure culture of the microorganism Streptomyces cyaneogriseus noncyanogenus, according to Claim 13, wherein said microorganism has spontaneously mutated, such that the microorganism is genetically altered but still retains the ability to synthesize agents LL-F28249 a, LL-F28249β, LL-F28249y, LL-F28249δ, LL-F28249ε, LL-F28249 ζ, LL-F28249η, LL-F28249e, LL-F28249t, LL-F28249K, LL-F28249 λ, LL-F28249µ, LL-F28249ν, and LL-F28249ω.
Claim 36
Dependent Claim
54 words
The biologically pure culture of the microorganism Streptomyces cyaneogriseus noncyanogenus, according to Claim 13, wherein said microorganism has been subjected to mutagenic means such that the microorganism is genetically altered but still retains the ability to synthesize agents LL-F28249a. LL-F28249β, LL-F28249y, LL-F28249δ, LL-F28249e, LL-F28249ζ, LL-F28249η, LL-F28249e, LL-F28249 , LL-F28249K, LL-F28249λ, LL-F28249µ, LL-F28249ν, and LL-F28249ω.
Claim 37
Dependent Claim
28 words
The compound according to Claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 additionally comprising: the pharmaceutically and pharmacologically-acceptable salts thereof.
Claim 38
Independent Claim
60 words
A method for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in warm-blooded animals, said method comprising: orally, parenterally or topically administering to an animal infected with helminths, arthropod ectoparasites or acarides, a prophylactically, therapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773.
Claim 39
Independent Claim
60 words
A method for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in warm-blooded animals, said method comprising: orally, parenterally or topically administering to an animal infected with helminths, arthropod ectoparasites or acarides, a prophylactically, therapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773.
Claim 40
Independent Claim
87 words
A method for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in warm-blooded animals, said method comprising: orally, parenterally or topically administering to an animal infected with helminths, arthropod ectoparasites or acarides, a prophylactically, thereapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces sp. LL-F28249, having deposit accession number NRRL 15773, containing agents designated LL-F28249 a , LL-F28249β, LL-F28249γ, LL-F282496, LL-F28249E, LL-F2824ζ, LL-F28249n, LL-F28249θ, LL-F28249 , LL-F28249K, LL-F28249λ, LL-F28249µ, LL-F28249v, and LL-F28249ω; or pharmaceutically and pharmacologically-acceptable salts thereof.
Claim 41
Independent Claim
87 words
A method for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in warm-blooded animals, said method comprising: orally, parenterally or topically administering to an animal infected with helminths, arthropod ectoparasites or acarides, a prophylactically, thereapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces sp. LL-F28249, having deposit accession number NRRL 15773, containing agents designated LL-F28249 a , LL-F28249β, LL-F28249γ, LL-F282496, LL-F28249E, LL-F2824ζ, LL-F28249n, LL-F28249θ, LL-F28249 , LL-F28249K, LL-F28249λ, LL-F28249µ, LL-F28249v, and LL-F28249ω; or pharmaceutically and pharmacologically-acceptable salts thereof.
Claim 42
Independent Claim
33 words
A method for the treatment of helmintic infections according to Claims 21 or 22, wherein about 0.1 mg per kg to 200 mg per kg is administered to an animal infected with helminths.
Claim 43
Independent Claim
50 words
A method for the control of plant nematodes, said method comprising: applying to the foliage of plants, the soil in which they are grown, or into the trunks thereof, a nematocidally-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773.
Claim 44
Independent Claim
50 words
A method for the control of plant nematodes, said method comprising: applying to the foliage of plants, the soil in which they are grown, or into the trunks thereof, a nematocidally-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773.
Claim 45
Independent Claim
76 words
A method for the control of plant nematodes, said method comprising: applying to the foliage of plants, the soil in which they are grown, or into the trunks thereof, a nematocidally-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773, containing agents designated LL-F28249a, LL-F28249β, LL-F28249y, LL-F282496, LL-F28249ε, LL-F28249ζ, LL-F28249η, LL28249θ, LL-F28249, LL-F28249 K, LL-F28249λ, LL-F28249µ, LL-F28249v, and LL-F28249w; or the pharmaceutically and pharmacologically-acceptable salts thereof.
Claim 46
Independent Claim
76 words
A method for the control of plant nematodes, said method comprising: applying to the foliage of plants, the soil in which they are grown, or into the trunks thereof, a nematocidally-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773, containing agents designated LL-F28249a, LL-F28249β, LL-F28249y, LL-F282496, LL-F28249ε, LL-F28249ζ, LL-F28249η, LL28249θ, LL-F28249, LL-F28249 K, LL-F28249λ, LL-F28249µ, LL-F28249v, and LL-F28249w; or the pharmaceutically and pharmacologically-acceptable salts thereof.
Claim 47
Independent Claim
20 words
A method according to Claims 24 or 25, wherein about 0.1 to 1.4 kg per hectare is applied to thereof.
Claim 48
Dependent Claim
54 words
An animal feed composition for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in meat-producing animals, said animal feed composition comprising: an edible solid carrier; and a phophylactically, therapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773.
Claim 49
Dependent Claim
54 words
An animal feed composition for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in meat-producing animals, said animal feed composition comprising: an edible solid carrier; and a phophylactically, therapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyaneogriseus noncyanogenus, having deposit accession number NRRL 15773.
Claim 50
Dependent Claim
83 words
An animal feed premix composition for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in meat-producing animals, said animal feed premix composition comprising: an edible carrier; and a prophylactically, therapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyanogriseus noncyanogenus, having deposit accession number NRRL 15773, containing agents designated LL-F28249a, LL-F28249β, LLF28249 γ, LL-F282496, LL-F28249e, LL-F28249ζ, LL-F28249η, LL-F28249 6, L1-F28249, LL-F28249K, LL-F28249λ, LL-F28249p, LL-F28249 vand LL-F28249ω; or the pharmaceutically and pharmacologically acceptable salts thereof.
Claim 51
Dependent Claim
83 words
An animal feed premix composition for the prevention, treatment or control of helmintic, arthropod ectoparasitic or acaridal infections in meat-producing animals, said animal feed premix composition comprising: an edible carrier; and a prophylactically, therapeutically or pharmaceutically-effective amount of the fermentation broth or whole mash of microorganism Streptomyces cyanogriseus noncyanogenus, having deposit accession number NRRL 15773, containing agents designated LL-F28249a, LL-F28249β, LLF28249 γ, LL-F282496, LL-F28249e, LL-F28249ζ, LL-F28249η, LL-F28249 6, L1-F28249, LL-F28249K, LL-F28249λ, LL-F28249p, LL-F28249 vand LL-F28249ω; or the pharmaceutically and pharmacologically acceptable salts thereof.
Claim 52
Dependent Claim
22 words
A composition according to Claims 27 or 28, wherein said effective amount is about 0.00001% to 5%, by weight, of said composition.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.